Remicade is NOT Rituxan/Rituximab/Rtx.
Remicade/Infliximab is a biological agent and monoclonal antibody like Rituximab, but works quite differently. It's being studied as a treatment for Wegs, but to my knowledge none of the Vasculitis centers are using it outside of studies. It does look promising--especially for "refractory" (ie, non-responsive to other drugs) systemic Wegs-- and may be the next Rituximab.
Remicade is an antibody to Tumor Necrosis Factor (TNF) which is made by the body. The role of TNF is to destroy malignant cells before they multiply and become larger tumors. So the obvious risk of Remicade is that you've taken away the body's Tumor Cop.
I searched PubMed and couldn't find any studies later than 2008 (other than 1 or 2 case studies). That probably indicates long-term studies are in progress right now. Maybe those of us who see Wegs specialists can ask our docs about Remicade at our next visits.
This 2008 paper is by Carol Langford at Cleveland Clinic
Drug insight: anti-tumor necrosis factor therapies... [Nat Clin Pract Rheumatol. 2008] - PubMed result
"Experience with the use of anti-TNF agents in patients with Wegener's granulomatosis or giant-cell arteritis has emphasized the crucial role of randomized trials in determining whether a treatment is effective, even in the face of promising preliminary data. Caution is necessary in clinical practice until such data become available."
A 2008 paper.
Novel therapies for anti-neutrophil cytoplasmic an... [Drugs. 2008] - PubMed result
"Safety concerns, notably of infection and malignancy, were common and need to be explored in subsequent trials. In addition, concomitant immunosuppressants and non-standardized definitions were major limitations, and future studies of these and newer agents must follow agreed standards of study design and reporting to facilitate clearer interpretation of the circumstances (e.g. disease stage, severity or organ involvement) under which these agents perform optimally. Consequently, use is still limited to centres experienced in such agents and mostly in the context of clinical trials."
This 2008 study includes 1 Weggie but the abstract doesn't say how s/he did:
Anti-tumor necrosis factor therapy: 6 year experie... [Isr Med Assoc J. 2008] - PubMed result
"Infliximab and etanercept have been included in the Israeli national list of health services since 2002 for rheumatoid arthritis and juvenile idiopathic arthritis, and since 2005 for psoriatic arthritis and ankylosing spondylitis. The regulator (Ministry of Health and health funds) mandates using fixed doses of infliximab as the first drug of choice and prohibits increased dosage. For other indications (e.g., vasculitis), anti-tumor necrosis factor therapy is given on a "compassionate" basis in severe refractory disease."
Cindy, I have no idea why your docs would be discussing Remicade when they haven't tried Ctx or Rtx--both proven therapies. I'd push for answers on that one if it were me.
Bookmarks